Randomized control trial to compare the effectiveness of mifepristone followed by misoprostol at 12 hours interval versus misoprostol alone in second trimester medical termination of pregnancy


  • Preet Kamal Bedi Department of Obstetrics and Gynecology, Government Medical College, Amritsar, Punjab, India
  • Arunima Saini Department of Obstetrics and Gynecology, Government Medical College, Amritsar, Punjab, India




Mifepristone, Misoprostol, Second trimester abortions


Background: Mifepristone priming in second trimester abortions not only decreases the induction-abortion interval (IAI) but also lessens the total misoprostol dose required and hence reduces adverse effects. The present study aims to compare the role of mifepristone priming 12 hours before misoprostol administration so as to increase patient compliance and shorten the duration of hospital stay.

Methods: This prospective study was conducted over a period of one year, on 50 patients requiring second trimester abortion, at Department of Obstetrics and Gynaecology, Government Medical College, Amritsar. The patients were divided into two groups with 1:1 randomization. In Group A, 25 women were given tablet mifepristone 200 mg orally followed 12 hours later by tablet misoprostol 400 µg per vaginum followed by the same dose 3 hourly for a maximum of five doses per 24 hours. In group B, 25 women received only tablet misoprostol 400 µg vaginally in the posterior fornix followed by the same dose 3 hourly for a maximum of five doses per 24 hours. Primary outcome was to compare the completeness of expulsion of products of conception by pelvic ultrasound after 48 hours of the last dose administered. Secondary outcome was to compare the Induction abortion interval (IAI), mean dose of misoprostol required, side effects, effect of parity, gestational age and cervical dilatation on IAI with both the regimens used.

Results: The success rate was 76% in group A and 64% in group B. The mean induction abortion interval in group A was 8.9±4.70 hours whereas in group B, it was 13.14±6.03 hours and this difference was statistically significant (p = 0.008). A statistically significant difference was also observed in mean dose of misoprostol required in group A and B being 1232.00±398.60 µg and 1584.00±423.94 µg respectively (p=0.004). The side effects were less in group A. Parity and cervical dilatation hold an inverse relation with the mean IAI whereas it has a direct relation with the gestational age.

Conclusions: Regimen involving mifepristone priming 12 hours before misoprostol is better than misoprostol alone regimen with significant reduction in IAI, mean dose of misoprostol and less side effects.



Gemzell-Danielsson K, Lalitkumar S. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management. Reprod Health Matters. 2008;16(31):162-72.

Dass A, Mukhopadahyay P, Dhawan S. Termination of midtrimester pregnancies by intra-amniotic injection of hypertonic saline. J Obstet Gynaecol India. 1975;25(3):323-30.

Weinberg PC, Shepard MK. Intraamniotic urea for induction of mid-trimester abortion. Obstet Gynecol. 1973;41(3):451-54.

Royal College of Obstetricians and Gynecologists. The care of women requesting induced abortion. evidence-based clinical guideline number 7. RCOG. 2011.

World Health Organization. Unsafe abortion: global estimates of the incidence of unsafe abortion and associated mortality in 2000. 4th ed. WHO:Geneva; 2004. Available at http://apps.who.int/iris/bitstream/handle/10665/42976/9241591803.pdf;jsessionid=B6AE2F99407F7B72511A786524B4050D?sequence=1

Pike JE. Total synthesis of prostaglandins. Fortschr Chem Org Naturst. 1970;28:313-42.

Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007;99(2):S160-7.

Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol. 2002;101(2):113-20.

Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet. 1991;338(8777):1233-6.

Baird DT, Norman JE, Thong KJ, Glasier AF. Misoprostol, mifepristone, and abortion. Lancet. 1992;339(8788):313.

Nagaria T, Sirmor N. Misoprostol vs mifepristone and misoprostol in second trimester termination of pregnancy. J Obstet Gynaecol India. 2011;61(6):659-62.

Chai J, Tang OS, Hong QQ, Chen QF, Cheng LN, Ng E, et al. A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion. Hum Reprod. 2009;24(2):320-4.

Ngoc NT, Shochet T, Raghavan S, Blum J, Nga NT, Minh NT, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2011;118(3):601-8.

Mukhopadhyay P, Bag TS, Kyal A, Bhuniya A, Saha TK. Second trimester abortion with vaginal misoprostol: is there any advantage with prior mifepristone priming? a comparative study. J South Asian Feder Obst Gynae. 2012;4(1):25-7.

Kulkarni KK. Pre-induction with Mifepristone for second trimester termination of pregnancy. J Obstet Gynaecol India. 2014;64(2):102-4.

Patel U, Chauhan K, Singhi S, Kanani M. Second trimester abortion-mifepristone and misoprostol or misoprostol alone? Int J Reprod Contracept Obstet Gynecol. 2013;2:315-9.

Patil SB, Biliangady HN. A comparative study using combination of Mifepristone and Misoprostol and single drug misoprostol only for second trimester abortion. Sch J App Med Sci. 2014;2(2D):840-3.

Kaushal A, Kaur K, Kaur P, Kaur A. Mifepristone plus Misoprostol versus Misoprostol for second trimester termination of pregnancy. Int J Curr Advanced Res. 2017;6(7):4472-5.






Original Research Articles